Negative feedback between secretory and cytosolic phospholipase A2 and their opposing roles in ovalbumin-induced bronchoconstriction in rats.
Phospholipase A2 (PLA2) hydrolyzes cell membrane phospholipids (PL) to produce arachidonic acid and lyso-PL. The PLA2 enzymes include the secretory (sPLA2) and cytosolic (cPLA2) isoforms, which are assumed to act synergistically in production of eicosanoids that are involved in inflammatory processes. However, growing evidence raises the possibility that in airways and asthma-related inflammatory cells (eosinophils, basophils), the production of the bronchoconstrictor cysteinyl leukotrienes (CysLT) is linked exclusively to sPLA2, whereas the bronchodilator prostaglandin PGE2 is produced by cPLA2. It has been further reported that the capacity of airway epithelial cells to produce CysLT is inversely proportional to PGE2 production. This seems to suggest that sPLA2 and cPLA2 play opposing roles in asthma pathophysiology and the possibility of a negative feedback between the two isoenzymes. To test this hypothesis, we examined the effect of a cell-impermeable extracellular sPLA2 inhibitor on bronchoconstriction and PLA2 expression in rats with ovalbumin (OVA)-induced asthma. It was found that OVA-induced bronchoconstriction was associated with elevation of lung sPLA2 expression and CysLT production, concomitantly with suppression of cPLA2 expression and PGE2 production. These were reversed by treatment with the sPLA2 inhibitor, resulting in amelioration of bronchoconstriction and reduced CysLT production and sPLA2 expression, concomitantly with enhanced PGE2 production and cPLA2 expression. This study demonstrates, for the first time in vivo, a negative feedback between sPLA2 and cPLA2 and assigns opposing roles for these enzymes in asthma pathophysiology: sPLA2 activation induces production of the bronchoconstrictor CysLT and suppresses cPLA2 expression and the subsequent production of the bronchodilator PGE2.
Offer
Sarit
S
Institute of Biochemistry, Faculty of Agriculture, The Hebrew University, Rehovat, Jerusalem.
Yedgar
Saul
S
Schwob
Ouri
O
Krimsky
Miron
M
Bibi
Haim
H
Eliraz
Abraham
A
Madar
Zecharia
Z
Shoseyov
David
D
D000818:Animals; D001249:Asthma / Q000139:chemically induced / Q000201:enzymology / Q000503:physiopathology*; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry; D016084:Bronchoconstriction / Q000187:drug effects; D003600:Cytosol / Q000201:enzymology*; D015232:Dinoprostone / Q000032:analysis; D004791:Enzyme Inhibitors / Q000494:pharmacology; D025461:Feedback, Physiological; D015289:Leukotrienes / Q000032:analysis / Q000737:chemistry; D008168:Lung / Q000378:metabolism; D008297:Male; D010047:Ovalbumin; D010741:Phospholipases A / Q000037:antagonists & inhibitors / Q000378:metabolism*; D054467:Phospholipases A2; D051381:Rats; D011914:Rats, Inbred BN
D004791:Enzyme Inhibitors; D015289:Leukotrienes; D010047:Ovalbumin; D010741:Phospholipases A; D054467:Phospholipases A2; D015232:Dinoprostone